Ozlem Inci

Dr. Ozlem Inci

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2023 in Journal of Emergencies, Trauma, and Shock
Verified
Journal Article
Open access
OIOzlem Inci
Ozlem Inci
YAYusuf Ali Altuncı
Yusuf Ali Altuncı
OCOzge Can
Ozge Can
FAFunda Karbek Akarca
Funda Karbek Akarca
MEMurat Ersel
Murat Ersel
Introduction: Focused Assessment with Sonography for Trauma (FAST) has attracted attention for its use in the detection of intra-abdominal pathology for pediatric patients. However, computed tomography (CT) remains the gold standard for the assessment of blunt torso trauma. The study examines the effectiveness of FAST both in the detection of intra-abdominal pathology in pediatric patients (<19 years) with blunt torso trauma and in the determination of the need for CT for further examination. Methods: The study was designed as a retrospective observational investigation of diagnostic value. The pediatric patients who were admitted to the Emergency Department with blunt torso trauma between January 2013 and October 2016 were included in the study. The sample of the study comprised 255 patients who met the inclusion criteria. The primary outcome was the effectiveness of FAST in the detection of intra-abdominal pathology and the determination of the need for CT. The secondary outcome was to identify the agreement between CT and FAST for intra-abdominal injuries. The Chi-square test and Fisher’s exact test were used for comparisons. A logistic regression model was developed to determine the variables that independently affect the agreement between FAST and CT. Results: FAST was determined to have low sensitivity (20.3%) despite its high specificity (87%). However; FAST had a good negative likelihood ratio. There was a poor agreement between CT and FAST in terms of the presence of both intra-abdominal and intrathoracic injuries in pediatric patients with blunt trunk trauma. The error rate of FAST increased by five-fold, especially in the presence of concomitant thorax trauma. However, FAST had a good negative likelihood ratio. Conclusion: FAST should not be regarded as an equivalent tool to CT for pediatric patients with blunt torso trauma. It is, instead, a noteworthy complementary tool that is a negative predictor.

20 October 2023 in Emergency Medicine International
Verified
Journal Article
Open access
PDF file
MKMeltem Songur Kodik
Meltem Songur Kodik
OIOzlem Inci
Ozlem Inci
ZÇZeynep Dila Çetin
Zeynep Dila Çetin
EGEmine Nihal Mete Gokmen
Emine Nihal Mete Gokmen
FAFunda Karbek Akarca
Funda Karbek Akarca
This study aimed to calculate the LACE index in patients who admitted to the emergency department (ED) with hereditary angioedema (HA) diagnosed and to predict recurrent admissions of patients. In this single-center study, patients aged 18 or higher who were admitted to the ED diagnosed with HA were included over a 12-year period. 35 patients diagnosed with code E88.0 were evaluated according to electronic file records. The number of admissions to the ED in the last 6 months was 2. The LACE index was 4, and risk was 71.4%. The patients admitted to the hospital in the last 30 days had a higher rate of admission to the hospital in the last 6 months ( < 0.001). The LACE index at admission predicted 30 days admission with (AUC = 0.75, 95% CI (0.56–0.91)) acceptable discrimination. The LACE index and the number of admissions in the last 6 months included in the evaluation can be considered predictive in recurrent ED admissions of HA patients. However, the distribution of LACE-risk groups is no priority. Therefore, the low-, medium-, or high-risk level of LACE index values should be not taken into consideration in readmission of such patients.

29 September 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
CACanan Akman
Canan Akman
BEBusra Erdem
Busra Erdem
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
OIOzlem Inci
Ozlem Inci
MUMehmet Unaldi
Mehmet Unaldi
OKOzgur Karcioglu
Ozgur Karcioglu
Introduction/Objective: Immunosuppressed Patients (ISP) — defined by congenital or acquired deficiencies in systemic defense mechanisms — are disproportionately susceptible to viral respiratory infections. Agents such as SARS-CoV-2, Respiratory Syncytial Virus (RSV), influenza A and B, and Cytomegalovirus (CMV) cause significant morbidity in both immunocompetent and immunosuppressed individuals. Clinical manifestations range from mild influenza-like illness to severe pneumonia, respiratory failure, multiorgan dysfunction, and concurrent bacterial infections. Methods: A narrative synthesis of the literature was performed using Medline, CINAHL, Web of Science, and Scopus using relevant keywords ("immunosuppressed patients", "pneumonia", "lung infection", "antiviral", "cytomegalovirus", "influenza", "RSV") for publications between January 2000 and March 2026. Where available, Cochrane systematic reviews, meta-analyses, and high-quality randomised controlled trials were given precedence in the narrative synthesis; systematic review and meta-analytic procedures, including PRISMA guidelines, were not applied. Case reports, editorials, and opinion articles were excluded, other than a small number of case series describing rare therapeutic strategies for which no higher-level evidence was available. Evidence was collated narratively and presented in tabular format. Results: Although numerous antiviral compounds have been developed and studied, the optimal agent for managing severe viral infections in ISP remains uncertain. Empiric oseltamivir for influenza is typically initiated immediately upon clinical suspicion. Other antivirals — including ganciclovir for CMV, cidofovir for adenovirus, and ribavirin for RSV or parainfluenza — are generally reserved for confirmed or highly suspected infections in high-risk populations. The safety profile of each agent must be evaluated individually before initiating the treatment. Discussion: Direct-acting antivirals achieve faster virologic clearance but do not consistently reduce shortterm mortality in ISP. Antiviral selection requires integration of pathogen identity, timing of therapy, underlying immune deficit, and individual risk-benefit assessment. Novel agents and combination strategies warrant further investigation in this population. Conclusion: ISP with viral pneumonia represents a clinically complex, high-risk group requiring individualized treatment strategies, including antiviral agents, vigilant safety monitoring, and proactive preventive measures, especially vaccination. Virologic clearance benefits associated with direct-acting antivirals such as remdesivir do not consistently translate into a short-term mortality benefit, underscoring the need for outcome- specific interpretation of the evidence. A nuanced understanding of the available antiviral armamentarium is essential to optimise outcomes in this vulnerable population.

27 October 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
GYGokhan Yılmaz
Gokhan Yılmaz
AEAsim Bedri Erdem
Asim Bedri Erdem
MUMehmet Unaldi
Mehmet Unaldi
BEBusra Erdem
Busra Erdem
OIOzlem Inci
Ozlem Inci
OKOzgur Karcioglu
Ozgur Karcioglu
Introduction/Objective: Opioids remain indispensable analgesics for acute, cancer-related, and selected chronic pain, yet their use is increasingly constrained by the opioid crisis and by opiophobia, an excessive, often irrational fear of opioid prescribing and use. This review synthesises evidence on opioid pharmacology, clinical applications, adverse effects, and opiophobia. Methods: This structured narrative review followed the SANRA criteria; PRISMA and PRISMA-ScR frameworks were not applied. Five databases (Google Scholar, PubMed, Scopus, Web of Science, MEDLINE; 2010-2026) were searched, prioritising systematic reviews, meta-analyses, randomised trials, and guidelines. Sixty-nine sources were synthesised. Results: Opioids act mainly via μ-opioid receptors, suppressing ascending nociceptive transmission and enhancing descending inhibition. Agents differ in potency, onset, duration, metabolism, and adverse-effect profiles. Constipation, nausea, and sedation are common; respiratory depression, although uncommon at titrated doses, is the most serious hazard. Opiophobic attitudes were reported in up to 80.2% of emergency physicians, and up to 64.4% of cancer patients held extreme addiction concerns. The pooled prevalence of opioid use disorder or dependence during long-term opioid therapy for chronic non-cancer pain was 9.3% (95% CI 5.7-14.8%). Discussion: Attitudinal barriers, rather than pharmacological limitations alone, drive undertreatment of pain, and regulatory overcorrection after the opioid crisis has created a secondary burden of inadequate analgesia. Risk stratification, multimodal analgesia, and structured monitoring can limit opioid exposure while preserving effective analgesia. Conclusion: Opioids remain effective and manageable under appropriate supervision. Balanced, evidencebased prescribing frameworks, combined with prescriber and patient education, are essential to reduce harm from both opioid misuse and inadequate analgesia.

9 October 2026 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
FGFatma Mutlu Kukul Güven
Fatma Mutlu Kukul Güven
Asli Bahar UcarAsli Bahar Ucar
Asli Bahar Ucar
OIOzlem Inci
Ozlem Inci
MUMehmet Unaldi
Mehmet Unaldi
BABurak Akin
Burak Akin
OKOzgur Karcioglu
Ozgur Karcioglu
Introduction/Objective: Pain affects approximately 30% of community-dwelling older adults and more than half of nursing-home residents but remains undertreated because age-related pharmacokinetic and pharmacodynamic changes render standard analgesic dosing hazardous. This review synthesises the evidence on rational analgesic prescribing in older adults, comparing the American Geriatrics Society 2023 Beers Criteria with STOPP/START version 3. Methods: In this structured narrative review, PubMed/MEDLINE, Embase and the Cochrane Library were searched (January 2000-May 2026), combining analgesic-class terms with the Beers Criteria, STOPP/START, potentially inappropriate medications, deprescribing and older age. Systematic reviews, meta-analyses, randomised trials, large observational studies and guidelines in English were eligible; studies confined to patients younger than 65 years were excluded. Results: Analgesics are principal drivers of inappropriate prescribing: STOPP/START version 3 identified at least one potentially inappropriate medication in 73% of geriatric outpatients versus 56% under version 2, NSAIDs and aspirin being the most prevalent new criteria. The Beers Criteria designate meperidine, non-selective oral NSAIDs, anticholinergic tricyclic antidepressants, and opioid-benzodiazepine or opioidgabapentinoid combinations as highest risk; meperidine is most strongly associated with unplanned hospitalisation (OR 2.37). Discussion: The instruments are complementary, not interchangeable: the Beers Criteria offer broader drug-disease coverage but are aligned with the United States formulary, whereas STOPP/START is bidirectional and more prescriptive on dose and renal thresholds. Neither has been shown to reduce falls, hospitalisation or mortality in adequately powered trials. Conclusion: Stepwise multimodal analgesia beginning with paracetamol and topical agents, initiated at low doses and titrated slowly, with comprehensive geriatric assessment and regular medication review, remains the evidence-based standard of care.

22 June 2021 in Research Square
Verified
Preprint
Open access
PDF file
MKMeltem Songur Kodik
Meltem Songur Kodik
EÖEsin Öztürk
Esin Öztürk
IUİlhan Uz
İlhan Uz
EÖEnver Özçete
Enver Özçete
OIOzlem Inci
Ozlem Inci
MEMurat Ersel
Murat Ersel
Introduction: Our study aimed to analyse the effectiveness of four scoring models in predicting mortality of intensive care unit (ICU) hospitalized COVID-19 patients. The models used in this regard were: Rapid Emergency Medicine Score (REMS), Charlson Comorbidity Index (CCI), Acute Physiology and Chronic Health Evaluation II (APACHE-II), and the Sequential Organ Failure Assessment (SOFA).Materials and Methods: A single-centre and retrospective analysis was carried out by considering definitive or probable COVID-19 patients hospitalized our hospital’s ICU unit. Patients who were admitted to our hospital’s ED between 11.03.2020 – 31.12.2020, and transferred directly to ICU from the ED due to being diagnosed with COVID-19 were included in our study. 411 patients above 18 years old were found appropriate for the study.Results: Among the patients, the mean age was 69 and 61.6% were male. Laboratory values such as creatinine, potassium(K), white blood cells(WBC), hematocrit(HTC), pH, and physiological findings such as mean arterial pressure, systolic and diastolic blood pressure, FiO2 were found statistically significant (p<0.05). Besides, comorbidities were observed in 368(89.5%) patients, and malignancy and dementia were statistically associated with death (p<0.001 and 0.019, respectively). All four of the scoring systems (REMS, CCI, APACHE-II, and SOFA) were statistically an indicator of in-hospital mortality (p0.05).Conclusion: We investigated that REMS, CCI, APACHE-II, and SOFA were effective in determining the in-hospital mortality of critically ill COVID-19 patients; however, no remarkable superiority existed between each other. These models may be guiding for ED physicians in terms of risk classification.